Company History

DRG International, founded in 1970, is a multinational specialty clinical diagnostics and medical equipment manufacturer and distributor with successful operations in more than 110 countries.

FOR MORE THAN 45 YEARS, DRG INTERNATIONAL HAS BEEN A LEADING INNOVATOR IN DIAGNOSTICS AND MEDICAL EQUIPMENT WORLDWIDE. THE FOLLOWING EVENTS HAVE SHAPED THE HISTORY OF DRG:

2020

DRG´s headquater DRG International, Inc., is celebrating 50th anniversary!

2019

DRG is certified according to EN ISO 13485:2016
DRG won a trophy at the French exibition JIB in Paris. The tophy was announced for "Processes and Technological Advances for Biological Analysis with Hepcidin 25 (bioactive) on DRG:HYBRiD-XL".
Salivary Hepcidin assay has been nominated for SelectScience Scientists' Choice Awards for Best New Clinical Product of 2018!
Acquisition of fertility test production of Bioserv Diagnostics GmbH (Germany): Anti Sperm Ab (serum), Anti Sperm Ab (seminal), Anti Ovarian Ab, Anti Zona Pellucida Ab ELISAs

2018

The unique assay Salivary Hepcidin was presented to the market
PSA was launched for the instrument DRG:HYBRiD-XL

2017

DRG launched 3 new assays for DRG:HYBRiD-XL:
Beta hCG, Free Estriol and Tumor Marker CA72-4

2016

DRG´s DRG:HYBRiD-XL is Winner or the German Design Award 2016, category "Special Mention"
Two new assays for DRG:HYBRiD-XL are launched: AFP, Calprotectin (Stool)
DRG launched a new Salivary ELISA: Progesterone HS

2015

DRG´s DRG:HYBRiD-XL is nominee for the German Design Award.
6 new assays for DRG:HYBRiD-XL are launched: CRP-HS, Hepcidin 25 (bioactive), Insulin, FSH, LH, Prolactin
DRG promotes the new DHT-optimized ELISA at MEDICA

2014

DRG is Winner of MDEA (Medical Design Excellence Awards) 2014 Bronze Award.
Launch of 12 new assays for automated Analyzer DRG:HYBRiD-XL: Androstenedione, Cystatin C, DHEA, DHEA-S, d-Dimer, Free Testosterone, HbA1c and Thyroid assays TSH, T3, T4, free T3, free T4

2013

First sales of automated Analyzer DRG:HYBRiD-XL at MEDICA 2013 together with 9 assays: 17-OH Progesterone, 25-OH Vitamin D (total), Aldosterone, CRP, Cortisol, Estradiol, Progesterone, Renin (activ) and Testosterone.
First training sessions on DRG:HYBRiD-XL for technicians and sales staff with participants from Algeria, UK, Indonesia, Saudi Arabia, Uzbekistan, Venezuela and UAE.

2012

Development and introduction of new test kits: 25-OH Vitamin D total, Aldosterone, Estrone Salivary and Hepcidin bioactive ELISA
Launch of the automated analyzer DRG:HYBRiD-XL to the market at AACC 2012

2011

Extention to the building of DRG Instruments in Marburg with new 730 square meter building.
September 2nd 2011, the new building is opened officially with a big party.
Development and introduction of a new test kit: Amyloid beta (1-40) serum ELISA

2010

Celebration of 40 Years of Excellence (1970 - 2010)
Development and introduction of new test kits: Renin (active), Amyloid beta Auto-Ab (Serum), L1-CAM, CRYPTO-1, Afamin, Cyr61, NOV ELISA
DRG acquires DIMA Diagnostica from bioMérieux

2009

Introduction of the world´s the first Hepcidin Test Kit
DRG developed a Connective Tissue Growth Factor (CTGF) Elisa which allows for clinical-value measurement in serum of CTGF in patients with chronic Hepatitis C Virus (HCV) and chronic liver disease
Vitamin Assays was added to the DRG product line
The new and unique closed system DRG:HYBRiD.XL was presented at MEDICA 2009 in Duesseldorf -
A fully automated analyzer for the simultaneous determination of immunoassays, as well as clinical chemistry

2008

DRG received two U.S. patents for its Hepcidin Test Kit
Start of the development of a closed system, our DRG:HYBRiD.XL, a fully automated analyzer for the simultaneous determination of immunoassays, as well as clinical chemistry.
DRG gained U.S. FDA approval for DRG's 17α-OH Progesterone Saliva kit (SLV-3140) for use worldwide
DRG developed a new Preeclampsia Test (PLGF ELISA) to determine the occurrence of preeclampsia in pregnant women. Preeclampsia, a multi-systemic disorder affecting mother and child at the end of the second trimester, is a major cause of maternal and perinatal mortality worldwide

2007

Launch of a new CHROMagar medium targeted to detect the Vancomycin Resistant Enterococcus faecalis and faecium and to differentiate them from the other bacteria
DRG announced its newest line of Veterinary ELISAs, including Canine, Equine, Rat and Lab animals
Introduction of a new Avian Influenza A ELISA Kit

2006

Launch of the Neonatal Screening PKU (Phenylketonuria). PKU is one of the most prevalent hereditary diseases in the metabolism of amino acids
Launch of the new ELISA PAPP-A

2005

DRG launched its Platinum Standard Tumor Markers

2004

Development of TUMOR MARKERS, CA 72-4, CA 125, CA 15-3, CA 19-9, Cyfra 21-1
Introduction of the Corticosterone & Estrone ELISAs

2003

Development and introduction of the world´s first Assay for measurement of Hepcidin
DRG aquired Novum-Diagnostics, Dietzenbach, and took over the production of more than 70 ELISAs for infectious diseases in DRG-Novum Branch lab

2002

Development and introduction of various Saliva kits including DHEA Saliva

2001

Dade Behring Technology transferred to DRG production of C5a and PAP - ELISAs

2000

Development and introduction of IGF1, IL-6, Cortisol- Saliva and Androstenedione ELISAs
Certification of QM-System EN ISO 9001: 1994 DNV

1999

Development and introduction of Insulin, PAPP-A, TGFß 2 ELISAs

1998

DRG moved to the New Building in Marburg
25 years DRG Instruments GmbH, Marburg, Germany

1997

Development and introduction of Leptin, TGFß 1, and ß-HCG ELISAs

1996

Development and introduction of Free Estriol ELISA

1995

Development and introduction of the first worldwide non-radioactive C-Peptide and Proinsulin Assays

1994

Development and introduction of of DHEA-S, Progesterone, Testosterone, PMSG, ß-HCG ELISAs
DRG Diagnostics Branch Office Berlin, Germany

1993

DRG Techsystems founded in Moscow, Russia
Developed and introduced 17-OH-Progesterone ELISA

1992

DRG Spol. s.r.o., founded in Brno, Czechoslovakia (Czech Republic)
Developed and Introduced AFP, HCG, FSH, Prolactin and LH

1991

DRG Biomed founded in St. Petersburg, Russia
Market entry of first Neonatal DRG Elisa: HPL

1990

DRG MEDTEK founded in Warsaw, Poland
Started R&D and production of ELISAs in Marburg, Germany

1988

DRG AG Zurich Switzerland

1985

DRG began in-house R&D Operations

1982

West and East Europe Expansion

1981

Entered Middle East Markets: Saudi Arabia, Kuwait and Iran
St. Jude Medical Bi-Leaflet Mechanical Heart Valve introduced to European Cardiac Surgery Market by DRG International

1975

DRG´s first participation at MEDICA, Düsseldorf, Germany

1974

DRG Instruments GmbH moved to Marburg, Germany

1973

Distribution of RIA's in Germany
DRG Instruments GmbH, Germany, founded in Munich

1970

DRG enters market in Europe, USSR, Poland, Yugoslavia
DRG International Inc. (NJ) founded by Dr. C.E. Geacintov